NCT04466150View on ClinicalTrials.gov

Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset

PHASE4Active, not recruitingINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

August 30, 2020

Primary Completion Date

December 31, 2026

Study Completion Date

July 31, 2027

Conditions

Relapsing Multiple SclerosisClinically Isolated Syndrome

Interventions

DRUG

Ocrelizumab

open label biomarker study

Trial Locations (1)

94158

University of California San Francisco, San Francisco

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

collaborator

Valhalla Foundation

OTHER

lead

University of California, San Francisco

OTHER